Literature DB >> 26186560

Healthy Late-preterm infants born 33-36+6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization.

Alison M Helfrich1, Cade M Nylund2, Matthew D Eberly2, Matilda B Eide2, David R Stagliano3.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of hospitalization for children <1year old and is more severe in premature infants.
OBJECTIVE: To assess whether late preterm (LPT) birth is an independent risk factor for RSV hospitalization and more severe RSV disease in children less than 24months old.
METHODS: We conducted a retrospective cohort study of children enrolled in the military health system. LPT birth was defined as 33+0 through 36+6weeks gestation. Patients who received palivizumab or had known risk factors for RSV were excluded. Adjusted hazard ratios (HR) for LPT birth were calculated using a Cox proportional hazard model, while controlling for sex and RSV season. Severity of illness was assessed by comparing the need for respiratory support, length of stay, and age at RSV hospitalization between LPT and term children.
RESULTS: A total of 599,535 children for 1,216,382 person-years were studied, of which 7597 children were admitted for RSV infection. LPT infants accounted for 643 (8.5%) of these RSV hospitalizations. The incidence density for RSV hospitalization of LPT infants was higher than term children (12.1 vs 7.8 per 1000 person-years). LPT infants had an increased adjusted risk for RSV hospitalization; specifically, those born 33+0 through 34+6weeks (HR 2.45; 95% confidence interval (CI) 1.96-3.07), and 35+0 through 36+6weeks (HR, 1.92; 95% CI, 1.66-2.22). LPT infants had longer hospital stays and required more respiratory support than term children.
CONCLUSIONS: LPT birth is an independent risk factor for severe RSV disease and need for hospitalization. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Bronchiolitis; Late preterm; Lower respiratory tract infection; Palivizumab; Prematurity; Respiratory syncytial virus

Mesh:

Year:  2015        PMID: 26186560     DOI: 10.1016/j.earlhumdev.2015.06.009

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  14 in total

1.  Letters to the Editor.

Authors:  I Mitchell; B Paes; K Lanctot; Rupesh Chawla; Aaron Chiu; Marianna Mitchell; Cecil Ojah; April Price; Sandra Seigel; Amanda Symington
Journal:  Paediatr Child Health       Date:  2015 Nov-Dec       Impact factor: 2.253

2.  Estimating seasonal onsets and peaks of bronchiolitis with spatially and temporally uncertain data.

Authors:  Sierra Pugh; Matthew J Heaton; Brian Hartman; Candace Berrett; Chantel Sloan; Amber M Evans; Tebeb Gebretsadik; Pingsheng Wu; Tina V Hartert; Rees L Lee
Journal:  Stat Med       Date:  2019-01-13       Impact factor: 2.373

3.  Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.

Authors:  M Cetinkaya; T K Oral; S Karatekin; B Cebeci; A Babayigit; Y Yesil
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-04-08       Impact factor: 3.267

4.  Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation.

Authors:  Eric A F Simões; Evan J Anderson; Xionghua Wu; Christopher S Ambrose
Journal:  PLoS One       Date:  2016-11-29       Impact factor: 3.240

5.  Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.

Authors:  Ahva Shahabi; Desi Peneva; Devin Incerti; Kimmie McLaurin; Warren Stevens
Journal:  Pharmacoecon Open       Date:  2018-03

6.  Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.

Authors:  Doyoung Kim; Mahwesh Saleem; Bosco Paes; Ian Mitchell; Krista L Lanctôt
Journal:  Clin Infect Dis       Date:  2019-08-30       Impact factor: 9.079

Review 7.  Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review.

Authors:  Josephine Mauskopf; Andrea V Margulis; Miny Samuel; Kathleen N Lohr
Journal:  Pediatr Infect Dis J       Date:  2016-07       Impact factor: 2.129

Review 8.  Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease.

Authors:  Josep Figueras-Aloy; Paolo Manzoni; Bosco Paes; Eric A F Simões; Louis Bont; Paul A Checchia; Brigitte Fauroux; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2016-09-14

9.  Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States.

Authors:  Rohan C Parikh; Kimmie K McLaurin; Andrea V Margulis; Josephine Mauskopf; Christopher S Ambrose; Melissa Pavilack; Sean D Candrilli
Journal:  Infect Dis Ther       Date:  2017-09-02

10.  Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan.

Authors:  Hsin Chi; Ching-Hu Chung; Yuh-Jyh Lin; Chyi-Her Lin
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.